Trogenix | 4biocapital

top of page

HOME
ABOUT US
- SOCIAL IMPACT
STRATEGY
TEAM
PORTFOLIO
- CURRENT PORTFOLIO
- PAST PORTFOLIO
NEWSROOM
CONTACT
More

Use tab to navigate through the menu items.

NEWSROOM

Nov 18

4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

ARCHIVE

November 2024
October 2024
May 2024
April 2024
March 2024
January 2024
November 2023
August 2023
June 2023
May 2023
December 2022
November 2022
October 2022
September 2022
June 2022
April 2022
March 2022
February 2022
January 2022
December 2021

SEARCH BY TAGS

FOLLOW US

4BIO Capital is a trading name of 4BIO Partners LLP which is authorised and regulated by the Financial Conduct Authority (Reference Number 842764)

4BIO Partners LLP is an SEC Registered Investment Advisor number 801-121342

© 2015-2024 by 4BIO Partners LLP

bottom of page